Investors may be asking whether Moderna's current share price reflects its underlying worth, or if the market is mispricing ...

In the latest trading session, Moderna (MRNA) closed at $49.20, marking a -1.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.11%. On the other hand, ...

Moderna's full pipeline may fuel long-term growth.

Broader biotech positioning aligns with movements tracked across the nasdaq ecosystem.

Piper Sandler expects Moderna to generate $2.07 billion in product sales in 2026, driven largely by its next‑generation COVID vaccine, mNEXSPIKE, according to Investing.com. The FDA is set to review ...

They aren't just "pandemic stocks." ...

The FDA had previously rejected Moderna's application, refusing even to review it after concluding Moderna hadn't done sufficient safety testing. Now, Moderna is promising to do additional testing to ...

Moderna (MRNA) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

Moderna is scaling its mRNA production capabilities and hiring specialized engineers, as its stock surges over 75% YTD amid a shift beyond COVID-19 vaccines.

European Medicines Agency approves Moderna's mRNA flu vaccine with strong efficacy in older adults. US FDA initially declines ...